Related references
Note: Only part of the references are listed.Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma
Shruti Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
Victoria Gutgarts et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma
Zhitao Ying et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Samantha Jaglowski et al.
BLOOD (2019)
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
Marcelo C. Pasquini et al.
BLOOD (2019)
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Mark A. Perazella et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Nephrotic syndrome associated with hemophagocytic syndrome
O. Thaunat et al.
KIDNEY INTERNATIONAL (2006)
Share Paper
